At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Beta-glucan (Glucan #300®)dietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans, a Pilot Study
In Brief
A clinical study evaluating Beta-glucan (Glucan #300®) for Immunologic Deficiency Syndromes. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to test wether orally administered Beta-glucan has systemic effects in humans.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsImmunologic Deficiency Syndromes
CountriesNetherlands
Collaborators--
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedNov 2012
Enrollment StartMay 2013
Primary CompletionJul 2013
TodayJul 2026
First PostedNov 16, 2012
Enrollment StartMay 1, 2013
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.6 years ago
Interventions
Beta-glucan (Glucan #300®)dietary